Lewis R B, Matzke D S, Albrecht T B, Pollard R B
Rev Infect Dis. 1986 Jul-Aug;8 Suppl 4:S434-8. doi: 10.1093/clinids/8.supplement_4.s434.
Evaluation of the in vitro neutralizing activity of 30 immunoglobulin G (IgG) preparations and seven batches of pooled plasma against human cytomegalovirus (CMV) was performed by plaque-reduction assays. There were definite differences detected by these methods that could permit the selection of preparations with highest titers for clinical trials. The addition of guinea pig complement to the plaque-reduction assay enhanced inhibition of CMV; thus, guinea pig complement should be used in assays of IgG preparations. There was no relationship between the ELISA-derived optical density values of the IgG samples and the titers determined by plaque neutralization. These data suggest that the results of plaque-reduction neutralization assays provide important information about preparations of antibody that may be selected for patient administration. The preparations selected for their high titers by neutralization assays differ significantly from those identified by another method.
通过蚀斑减少试验对30种免疫球蛋白G（IgG）制剂和7批混合血浆针对人巨细胞病毒（CMV）的体外中和活性进行了评估。这些方法检测到了明确的差异，这可以允许选择具有最高滴度的制剂用于临床试验。在蚀斑减少试验中添加豚鼠补体可增强对CMV的抑制作用；因此，在IgG制剂的检测中应使用豚鼠补体。IgG样品的ELISA衍生光密度值与蚀斑中和法测定的滴度之间没有关系。这些数据表明，蚀斑减少中和试验的结果提供了有关可能被选择用于患者给药的抗体制剂的重要信息。通过中和试验因其高滴度而选择的制剂与通过另一种方法鉴定的制剂有显著差异。
